The CAPNETZ Study – the centerpiece of the CAPNETZ STIFTUNG
Centerpiece of the CAPNETZ STIFTUNG is the CAPNETZ study devoted to community-acquired pneumonia (CAP) in adults. With its ever-growing unique database and biomaterial collection, the CAPNETZ study investigates scientific issues relating to CAP. While open questions remain, the engagement of our associated scientists, clinicians and physicians is unbroken.
The current foci of the study are reciprocal interactions between CAP and comorbidities, improved pathogen diagnostics, identification of patient risk groups, and the role of immunosuppression in CAP.
The CAPNETZ study is an observational study on community-acquired pneumonia (CAP) in adults and the main project of the CAPNETZ STIFTUNG. After two decades of study implementation, CAPNETZ STIFTUNG looks back on a comprehensive database of over 14 000 CAP patients. This unique data collection is the basis on which many projects in fundamental and clinical research on CAP and other respiratory infections are built. Continue for more details.
2002: Start of the research initiative
The foundation of the ambitious project was laid in 2002: Through funding of the German ministry for education and research a “network of competence” was initiated around several clinical centres in Germany. The network encompassed a study infrastructure for a prospective, longitudinal, and multi-centre observational study, and a detailed data and biomaterial collection. Since then, every year several hundred CAP patients are recruited and observed over a span of 180 days. Associated clinical data, microbiological and laboratory results, and patient samples are collected and stored centrally.
Since the start of the CAPNETZ study, a multitude of scientific questions have been answered owing to the data collection on pathogens and their epidemiology, treatments and antibiotic resistance, and on optimal therapy management for the patients.
A prognostic factor: pathogen identification
A rapid identification of the etiological agent facilitates focused antibiotic treatment. Therefore, the CAPNETZ study protocol was amended in 2017 with improved microbiological diagnostics. Previously, a reduction in cases with identified pathogen was observed. To overcome structural and economic limitations in diagnostic procedures at the clinics, two centralized diagnostics units were added to the study infrastructure, to improve patient outcome and epidemiological surveillance.
Collecting epidemiology data
A primary objective of the CAPNETZ study is the acquisition of data on prevalence and incidence of CAP in relation to patient risk factors such as underlying chronic illnesses. By recording comorbidities of CAP patients, interactions between pathological mechanisms can be uncovered. CAP constitutes an inflammatory event that affects the course of pre-existing health conditions and can contribute to complications and adverse events of these conditions. Such disease interactions need to be considered in the health management of the individual patient.
CAP and immunosuppression
Over the course of time CAP-research has adapted to novel scientific inquiries. Alongside this, the CAPNETZ study also evolved: Since 2017 patients with immunosuppression can be recruited. Immunosuppression as consequence of infection, chronic illness, medication or organ transplantation, results in poor CAP prognosis. Here, the spectrum of potential underlying pathogens differs from the population of non-immunocompromised patients, which we know much more about. Accordingly, clinical guidelines on CAP management might not be appropriate for immunocompromised patients. Therefore, CAP management strategies need to be established for persons with clinically relevant immunosuppression. This is also true for patients with HIV – another study population which has been included in the CAPNETZ study since the protocol amendment in 2017. Answering questions on HIV-specific patient risk factors in respect to CAP such as age, immune state, and HI-viral load, are objectives of the reformed CAPNETZ study.
Identification of at-risk patients
Generally, the identification of patient groups that are at a high risk for complications and mortality is crucial for CAP management. Therefore, research focusses on creation of an emergency protocol for CAP in the stationary sector, and primarily, on the description of patient risk factors.
Further objectives of the CAPNETZ study are
- Improved disease prevention by evaluation of vaccination readiness against influenza, Covid-19, and pneumococcal disease
- Improved diagnostics by conflation analysis of clinical and microbiological data
- Establishment of a database on antibiotic resistance
- Investigations of pathogen-host interactions
- Expansion of the central biomaterial- and pathogen database
From the study to the practice
The coordination of numerous study centres, diagnostics and the biobank is very complex and requires a centralised data collection system, which is accessible by all involved bodies through our certified study portal.
Patient recruitment begins with patient information and consent. At the baseline visit, clinical data on disease symptoms, the medical history of the patient including comorbidities and other risk factors, risk scores, lab results, microbiological results, and medications are documented. Different biological samples are collected and sent to the biobank in Hannover: EDTA-blood, serum, plasma, urine, PAXGene-RNA and lower respiratory tract samples (e.g. sputum). Upper respiratory material is also send to the central bacteriology and virology labs in Lübeck and Freiburg. Hospitalised patients undergo further examinations and sampling on days 3 and 7. Two further long-term follow-ups are conducted also for ambulatory patients and consist of a telephone visit for checking patient status after 28 and 180 days.
Patient safety and promotion of scientific research are our highest priority
The CAPNETZ study is conducted according to pre-determined ethical standards. Coherent data monitoring ensures not only completeness and plausibility of our data, but also makes sure that the patient’s consent is always respected. Distribution of our data to researchers requires an intense data clearing process. Thus, in order to access our database, research institutions can officially apply .
Our data informs the national S3 guideline
Research on CAPNETZ data is frequently published at high-ranking scientific journals, and constitutes a fundamental source of the national S3 guideline on epidemiology, diagnosis, therapy, and management of CAP. The guideline is the result of a collaboration between the Paul-Erlich Gesellschaft, the German Respiratory Society, the German Infection Society, and the management board of the CAPNETZ STIFTUNG.